Last reviewed · How we verify

Orphalan — Portfolio Competitive Intelligence Brief

Orphalan pipeline: 1 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
D-Penicillamine D-Penicillamine marketed Heavy metal chelator / immunosuppressant Heavy metals (copper, mercury, lead); disulfide bonds in proteins Rheumatology / Toxicology
Penicillamine (W12-W60) Penicillamine (W12-W60) phase 3 Heavy metal chelator / immunomodulator Copper, heavy metals (non-specific chelation); collagen cross-linking inhibition Rare disease / Metabolic disorder
TETA 4HCl formulation TETA 4HCl formulation phase 3 Potassium channel blocker Potassium channels Cardiovascular
TETA 4HCL (60-<W108) TETA 4HCL (60-<W108) phase 3 Potassium channel blocker Potassium channels Cardiovascular
TETA 4HCL (W12-60) TETA 4HCL (W12-60) phase 3 Potassium channel blocker Potassium channels Cardiovascular
Penicillamine (D1-W12) Penicillamine (D1-W12) phase 3 Chelating agent Heavy metal ions (copper, mercury, lead); thiol-reactive compounds Rare disease / Metabolic disorder

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Alexion Pharmaceuticals, Inc. · 1 shared drug class
  3. Biogen · 1 shared drug class
  4. D'Youville College · 1 shared drug class
  5. Essentialis, Inc. · 1 shared drug class
  6. M.D. Anderson Cancer Center · 1 shared drug class
  7. Mt. Sinai Medical Center, Miami · 1 shared drug class
  8. National Center for Research Resources (NCRR) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Orphalan:

Cite this brief

Drug Landscape (2026). Orphalan — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orphalan. Accessed 2026-05-13.

Related